Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

D'Ambrosio, Lorenzo
Touati, Nathan
Blay, Jean-Yves
Grignani, Giovanni
Flippot, Ronan
Czarnecka, Anna M
Piperno-Neumann, Sophie
Martin-Broto, Javier
Sanfilippo, Roberta
Katz, Daniela
Duffaud, Florence
Vincenzi, Bruno
Stark, Daniel P
Mazzeo, Filomena
Tuchscherer, Armin
Chevreau, Christine
Sherriff, Jenny
Estival, Anna
Litière, Saskia
Sents, Ward
Ray-Coquard, Isabelle
Tolomeo, Francesco
Le Cesne, Axel
Rutkowski, Piotr
Stacchiotti, Silvia
Kasper, Bernd
Gelderblom, Hans
Gronchi, Alessandro
European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

January 2020

BACKGROUND: The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-spec...

Experience with eribulin in pretreated patients with advanced liposarcoma: A case series

Paioli A.
Setola E.
Palmerini E.
Cesari M.
Longhi A.

January 2020

Systemic treatments for advanced soft tissue sarcoma are limited. Eribulin showed activity in metast...

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

D'Ambrosio, L.
Touati, N.
Blay, J.Y.
Grignani, G.
Flippot, R.
Czarnecka, A.M.
Piperno-Neumann, S.
Martin-Broto, J.
Sanfilippo, R.
Katz, D.
Duffaud, F.
Vincenzi, B.
Stark, D.P.
Mazzeo, F.
Tuchscherer, A.
Chevreau, C.
Sherriff, J.
Estival, A.
Litiere, S.
Sents, W.
Ray-Coquard, I.
Tolomeo, F.
Cesne, A. le
Rutkowski, P.
Stacchiotti, S.
Kasper, B.
Gelderblom, H.
Gronchi, A.
European Org Res
Treatment Canc Soft Tissue Bone Sa

June 2020

Background The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-speci...

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

라선영

October 2017

BACKGROUND: A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced...

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine

Demetri, George D
Schöffski, Patrick
Grignani, Giovanni
Blay, Jean-Yves
Maki, Robert G
Van Tine, Brian A
Alcindor, Thierry
Jones, Robin L
D'Adamo, David R
Guo, Matthew
Chawla, Sant

October 2017

Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma ...

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Demetri, GD
Schöffski, P
Grignani, G
Blay, J-Y
Maki, RG
Van Tine, BA
Alcindor, T
Jones, RL
D'Adamo, DR
Guo, M
Chawla, S

October 2017

Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma ...

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Blay, Jean-Yves
Schoffski, Patrick
Bauer, Sebastian
Krarup-Hansen, Anders
Benson, Charlotte
D'Adamo, David R
Jia, Yan
Maki, Robert G

May 2019

BACKGROUND: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbaz...

Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin

Schöffski, Patrick
van Cann, Tom
Cornillie, Jasmien

April 2017

Eribulin in advanced liposarcoma and leiomyosarcoma

Setola, E
Noujaim, J
Benson, C
Chawla, S
PALMERINI, EMANUELA
Jones, R.l.

January 2017

Introduction: The heterogeneity of soft tissue sarcomas (STS) presents a formidable management chall...

Eribulin in advanced liposarcoma and leiomyosarcoma.

Setola, E
Noujaim, J
Benson, C
Chawla, S
Palmerini, E
Jones, RL

August 2017

Introduction The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challe...

Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma

고윤우
김승현
김지형
김창곤
심남석
정인경
한윤대
김상겸
라선영
김효송
이영한
백우열
신수진

August 2022

Purpose: Monotherapy with eribulin or gemcitabine has been found to be moderately effective in treat...

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Schöffski, Patrick
Ray-Coquard, Isabelle Laure
Cioffi, Angela
Bui, Nguyen Bin
Bauer, Sebastian
Hartmann, Joerg Thomas
Krarup-Hansen, Anders
Grünwald, Viktor
Sciot, Raf
Dumez, Herlinde
Blay, Jean-Yves
Le Cesne, Axel
Wanders, Jantien
Hayward, Carolyn
Marreaud, Sandrine
Ouali, Monia
Hohenberger, Peter
for the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)

October 2011

BACKGROUND: Eribulin inhibits microtubule dynamics via a mechanism distinct from that of other tubul...

Efficacy of Eribulin in Soft Tissue Sarcomas

Phillips, E
Jones, RL
Huang, P
Digklia, A

April 2022

Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options...

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

Patel, S.
von Mehren, M.
Reed, D. R.
Kaiser, P.
Charlson, J.
Ryan, C. W.
Rushing, D.
Livingston, M.
Singh, A.
Seth, R.
Forscher, C.
D'Amato, G.
Chawla, S. P.
McCarthy, S.
Wang, G.
Parekh, T.
Knoblauch, R.
Hensley, M. L.
Maki, R. G.
Demetri, G. D.

August 2019

BACKGROUND: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously-...

Efficacy of Eribulin in Soft Tissue Sarcomas.

Phillips, E.
Jones, R.L.
Huang, P.
Digklia, A.

January 2022

Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options...

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

D'Ambrosio, Lorenzo
Touati, Nathan
Blay, Jean-Yves
Grignani, Giovanni
Flippot, Ronan
Czarnecka, Anna M
Piperno-Neumann, Sophie
Martin-Broto, Javier
Sanfilippo, Roberta
Katz, Daniela
Duffaud, Florence
Vincenzi, Bruno
Stark, Daniel P
Mazzeo, Filomena
Tuchscherer, Armin
Chevreau, Christine
Sherriff, Jenny
Estival, Anna
Litière, Saskia
Sents, Ward
Ray-Coquard, Isabelle
Tolomeo, Francesco
Le Cesne, Axel
Rutkowski, Piotr
Stacchiotti, Silvia
Kasper, Bernd
Gelderblom, Hans
Gronchi, Alessandro
European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

January 2020

BACKGROUND: The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-spec...

Experience with eribulin in pretreated patients with advanced liposarcoma: A case series

Paioli A.
Setola E.
Palmerini E.
Cesari M.
Longhi A.

January 2020

Systemic treatments for advanced soft tissue sarcoma are limited. Eribulin showed activity in metast...

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

D'Ambrosio, L.
Touati, N.
Blay, J.Y.
Grignani, G.
Flippot, R.
Czarnecka, A.M.
Piperno-Neumann, S.
Martin-Broto, J.
Sanfilippo, R.
Katz, D.
Duffaud, F.
Vincenzi, B.
Stark, D.P.
Mazzeo, F.
Tuchscherer, A.
Chevreau, C.
Sherriff, J.
Estival, A.
Litiere, S.
Sents, W.
Ray-Coquard, I.
Tolomeo, F.
Cesne, A. le
Rutkowski, P.
Stacchiotti, S.
Kasper, B.
Gelderblom, H.
Gronchi, A.
European Org Res
Treatment Canc Soft Tissue Bone Sa

June 2020

Background The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-speci...

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

라선영

October 2017

BACKGROUND: A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced...

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine

Demetri, George D
Schöffski, Patrick
Grignani, Giovanni
Blay, Jean-Yves
Maki, Robert G
Van Tine, Brian A
Alcindor, Thierry
Jones, Robin L
D'Adamo, David R
Guo, Matthew
Chawla, Sant

October 2017

Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma ...

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Demetri, GD
Schöffski, P
Grignani, G
Blay, J-Y
Maki, RG
Van Tine, BA
Alcindor, T
Jones, RL
D'Adamo, DR
Guo, M
Chawla, S

October 2017

Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma ...

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Blay, Jean-Yves
Schoffski, Patrick
Bauer, Sebastian
Krarup-Hansen, Anders
Benson, Charlotte
D'Adamo, David R
Jia, Yan
Maki, Robert G

May 2019

BACKGROUND: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbaz...

Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin

Schöffski, Patrick
van Cann, Tom
Cornillie, Jasmien

April 2017

Eribulin in advanced liposarcoma and leiomyosarcoma

Setola, E
Noujaim, J
Benson, C
Chawla, S
PALMERINI, EMANUELA
Jones, R.l.

January 2017

Introduction: The heterogeneity of soft tissue sarcomas (STS) presents a formidable management chall...

Eribulin in advanced liposarcoma and leiomyosarcoma.

Setola, E
Noujaim, J
Benson, C
Chawla, S
Palmerini, E
Jones, RL

August 2017

Introduction The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challe...

Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma

고윤우
김승현
김지형
김창곤
심남석
정인경
한윤대
김상겸
라선영
김효송
이영한
백우열
신수진

August 2022

Purpose: Monotherapy with eribulin or gemcitabine has been found to be moderately effective in treat...

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Schöffski, Patrick
Ray-Coquard, Isabelle Laure
Cioffi, Angela
Bui, Nguyen Bin
Bauer, Sebastian
Hartmann, Joerg Thomas
Krarup-Hansen, Anders
Grünwald, Viktor
Sciot, Raf
Dumez, Herlinde
Blay, Jean-Yves
Le Cesne, Axel
Wanders, Jantien
Hayward, Carolyn
Marreaud, Sandrine
Ouali, Monia
Hohenberger, Peter
for the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)

October 2011

BACKGROUND: Eribulin inhibits microtubule dynamics via a mechanism distinct from that of other tubul...

Efficacy of Eribulin in Soft Tissue Sarcomas

Phillips, E
Jones, RL
Huang, P
Digklia, A

April 2022

Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options...

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

Patel, S.
von Mehren, M.
Reed, D. R.
Kaiser, P.
Charlson, J.
Ryan, C. W.
Rushing, D.
Livingston, M.
Singh, A.
Seth, R.
Forscher, C.
D'Amato, G.
Chawla, S. P.
McCarthy, S.
Wang, G.
Parekh, T.
Knoblauch, R.
Hensley, M. L.
Maki, R. G.
Demetri, G. D.

August 2019

BACKGROUND: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously-...

Efficacy of Eribulin in Soft Tissue Sarcomas.

Phillips, E.
Jones, R.L.
Huang, P.
Digklia, A.

January 2022

Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options...

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

D'Ambrosio, Lorenzo
Touati, Nathan
Blay, Jean-Yves
Grignani, Giovanni
Flippot, Ronan
Czarnecka, Anna M
Piperno-Neumann, Sophie
Martin-Broto, Javier
Sanfilippo, Roberta
Katz, Daniela
Duffaud, Florence
Vincenzi, Bruno
Stark, Daniel P
Mazzeo, Filomena
Tuchscherer, Armin
Chevreau, Christine
Sherriff, Jenny
Estival, Anna
Litière, Saskia
Sents, Ward
Ray-Coquard, Isabelle
Tolomeo, Francesco
Le Cesne, Axel
Rutkowski, Piotr
Stacchiotti, Silvia
Kasper, Bernd
Gelderblom, Hans
Gronchi, Alessandro
European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

January 2020

BACKGROUND: The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-spec...

Experience with eribulin in pretreated patients with advanced liposarcoma: A case series

Paioli A.
Setola E.
Palmerini E.
Cesari M.
Longhi A.

January 2020

Systemic treatments for advanced soft tissue sarcoma are limited. Eribulin showed activity in metast...

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

D'Ambrosio, L.
Touati, N.
Blay, J.Y.
Grignani, G.
Flippot, R.
Czarnecka, A.M.
Piperno-Neumann, S.
Martin-Broto, J.
Sanfilippo, R.
Katz, D.
Duffaud, F.
Vincenzi, B.
Stark, D.P.
Mazzeo, F.
Tuchscherer, A.
Chevreau, C.
Sherriff, J.
Estival, A.
Litiere, S.
Sents, W.
Ray-Coquard, I.
Tolomeo, F.
Cesne, A. le
Rutkowski, P.
Stacchiotti, S.
Kasper, B.
Gelderblom, H.
Gronchi, A.
European Org Res
Treatment Canc Soft Tissue Bone Sa

June 2020

Background The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-speci...

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Abstract

Extracted data

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Abstract

Extracted data

Related items

Related items